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Gene therapy for individuals infected with HIV has the potential to provide a once-only treatment that will act to reduce viral load,
preserve the immune system, andmitigate cumulative toxicities associated with highly active antiretroviral therapy (HAART). The
authors have been involved in two clinical trials (phase I and phase II) using gene-modified adult hematopoietic stem cells (HSCs),
and these are discussed as prototypic trials within the general field of HSC gene therapy trials for HIV. Taken as a group these
trials have shown (i) the safety of both the procedure and the anti-HIV agents themselves and (ii) the feasibility of the approach.
They point to the requirement for (i) the ability to transduce and infuse as many as possible gene-containing HSC and/or (ii) high
engraftment and in vivo expansion of these cells, (iii) potentially increased efficacy of the anti-HIV agent(s) and (iv) automation
of the cell processing procedure.
1. Introduction
Highly active antiretroviral therapy (HAART) has greatly
improved disease management for individuals infected with
HIV-1. However, it is often associated with toxicities, adverse
interactions with other drugs, and the emergence of viral
resistance [1]. The search for an HIV-1 vaccine has been
disappointing [2]. Gene-based therapies aim to inhibit HIV
replication by the use of an anti-HIV gene expressed intra-
cellularly; such genes include ribozyme, antisense, aptamer,
RNAi, zinc finger nuclease, dominant negative protein,
fusion inhibitor, intracellular antibody, and viral decoy
approaches [3–35]. Some of these genes have been shown
to be safe in phase I clinical trials [4, 10, 12, 17, 20, 28–
35]. Ribozymes are small catalytic RNA molecules that can
be engineered to target specific RNA sequences [4, 10, 19, 20,
24, 26, 27, 31, 32, 35–40].
The gene therapy vector OZ1 (also termed RRz2 in
publications) comprises a Moloney murine leukemia virus-
based, replication-incompetent gamma retroviral vector
(LNL6) containing a gene that encodes a ribozyme targeting
the overlapping vpr and tat reading frames of HIV-1 [4,
32, 36–39]. OZ1 has been shown to inhibit the replication
of laboratory and clinical isolates of HIV-1 in vitro [36–
39]. Resistance mutations in the region of HIV-1 targeted
by OZ1 were not observed in long-term cell culture [10,
27, 37, 39]. The concept tested in the two clinical trials
conducted by the present investigators and colleagues (phase
I and phase II) was that, OZ1-transduced CD34+ HSC
would engraft, divide, and differentiate in vivo to produce
a pool of mature myeloid and lymphoid cells protected
from productive HIV-1 replication and, in the case of the
phase II trial, that this protection could be measured by
differences in plasma HIV-1 RNA levels in the absence of
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antiretroviral therapy [32]. This concept is shown pictorially
in Figure 1. In both these prototypic trials, autologous
CD34+ HSC were transduced and administered without
the subject undergoing myeloablation or any form of bone
marrow conditioning.
2. Prototypic Phase I Trial Design
The prototypic phase I clinical trial [4] was conducted
using CD34+ HSC to assess the safety and feasibility of
ex vivo transduction and reinfusion of autologous OZ1-
transduced cells. The protocol involved injection of the
subjects with G-CSF to mobilize HSC into the periph-
eral blood, collection of the mononuclear cell fraction by
apheresis, selection of the CD34+ population, culture of
these cells in vitro with cytokines, their transduction with
control (LNL6) or therapeutic (OZ1) vectors, and finally cell
harvest and infusion (see Figure 2). This trial demonstrated
that the approach was safe and technically feasible and that
concurrent administration of antiretroviral therapy did not
inhibit stem cell mobilization or the ability to transduce HSC
in vitro. There were no serious adverse events related to the
gene transfer process or the gene transfer product during the
study period or the subsequent long-term safety followup.
Detection of the gene in peripheral blood cells and bone
marrow cells was found in some patients to be present out
to 3 years after a single infusion of these cells [4].
3. Prototypic Phase II Trial Design
In this randomized trial [32], subjects (1 : 1 randomization)
were infused with either gene or sham medium only
transduced autologous CD34+ HSC. The protocol of cell
selection, culture, and transduction was based on the phase
I trial, with some modifications. In addition (unlike the
phase I trial), the protocol included two antiretroviral
treatment interruptions (ATIs) to provide positive selective
pressure for OZ1-protected cells, and as a read-out for the
effectiveness of these protected cells in preventing further
HIV replication in vivo (see Figures 3(a) and 3(b)). The
impact of OZ1 on plasmaHIV-1 viral load was assessed at the
end of the second eight-week ATI (the primary endpoint).
Secondary endpoints of quantitative marking (presence of
gene) and expression (active RNA form) of OZ1, time-
weighted area under the curve for viral load (TWAUC),
CD4+ T lymphocyte count in absolute and percentage of T
lymphocytes (CD4%), presence of HIV-1 proviral DNA, and
thymic function (T cell receptor excision circles, TREC) were
assessed at the primary endpoint (weeks 47/48) and to week
100. The OZ1 treatment group participants are now enrolled
in a long-term safety followup protocol.
4. Regulatory Process
For the prototypic trials, approval was obtained from the
relevant Institutional Review Boards/Human Research Ethics
Committee as well as the Recombinant DNA Advisory
Committee (RAC), the Center for Biologics Evaluation and
Research (CBER), the United States Food and Drug Admin-
istration (FDA), and the Australian Therapeutic Goods
Administration (TGA). Safety parameters were assessed in
accordance with RAC, CBER, FDA, and TGA recommenda-
tions [41]. The majority of the other trials followed similar
routes of approval, predominantly in the USA (see Table 1).
5. Cell Processing
In both the prototypic phase I and phase II clinical trials
the cell processing involved the elements as depicted in
Figures 2 and 3(a). Apheresis was performed using the COBE
Spectra Apheresis System (Gambro) and the mononuclear
cell fraction subjected to CD34+ cell selection using the
CEPRATE SC Stem Cell Concentration System (CellPro Inc)
(initial subjects in phase I trial) [4] or the Isolex 300i Cell
Selection System (Nexell Therapeutics) (all other subjects
phase I and II trials) [4, 32].
5.1. Phase I Trial [4]. The CD34+ selected cell population
was placed into tissue culture with Iscove’s Modified Dul-
becco’s Medium (IMDM) containing the cytokines stem
cell factor (SCF) and megakaryocyte growth and develop-
ment factor (MGDF) at a concentration of 50 ng/mL and
100 ng/mL, respectively (Amgen Inc). Cells were split into
two equal aliquots and transduced on day 2 with either an
LNL6 control or the OZ1 retroviral vectors (Figure 2). In the
7 latter subjects, transduction was improved by the use of
RetroNectin resulting in a range of transduction from 7 to
57%. Cells were collected on day 3, and after release testing,
the two separately transduced HSC aliquots were combined
and infused into the subject from whom they were obtained.
The number of CD34+ HSC infused was in the range of
1–10 × 106/kg.
5.2. Phase II Trial [32]. Similar to the phase I trial, the
CD34+ selected cell population was placed into tissue culture
with Iscove’s Modified Dulbecco’s Medium (IMDM) con-
taining the cytokines stem cell factor (SCF) (Amgen) and
megakaryocyte growth and development factor (MGDF)
(Takara) at a concentration of 50 ng/mL and 100 ng/mL,
respectively. However in this case, subjects were randomized
to receive either sham (medium alone) or OZ1-transduced
CD34+ HSC (Figure 3(a)). Both treatment groups received
an equivalent dose of viable CD34+ cells/kg (9 × 106/kg)
and the infused cell product in the OZ1 treatment group
contained a mean of 54.0% OZ1-containing cells. Partici-
pants in the OZ1 group are now enrolled in a separate long-
term follow-up protocol which will continue for at least 15
years. To date, the longest follow-up period from the time of
infusion of the first participant is 6.5 years [32].
6. OZ1 Gene Marking (DNA) and OZ1
Expression (RNA)
In the prototypic phase I trial [4], hematopoietic progeny
cells containing either the LNL6 vector or OZ1 (derived
from the gene-modified CD34+ HSC) could be separately
Stem Cells International 3
Autologous
hematopoietic stem cells 
Macrophages
CD4+ cells
T lymphocyte development
Myeloid development
OZ1
Anti-HIV ribozyme =
delivery by retroviral vector
Figure 1: The figure shows the concept of introducing an anti-HIV gene (in this case a ribozyme) into hematopoietic stem cells. As these
cells mature and differentiate into T lymphocytes and myeloid cells, the anti-HIV gene is expressed in these cells potentially providing an
anti-HIV effect in cells susceptible to HIV.
Table 1
Target/mechanism of
action
Construct Results
Rev [30]
“Humanized” dominant-negative REV protein
(huM10) and nontranslated marker gene (FX) as an
internal control in retroviral vector
Gene marking in first months, then low or
undetectable except in one patient when viral load
increased. No serious adverse events.
RRE decoy [12, 33]
Retroviral-mediated transfer of an RRE decoy gene
into bone marrow CD34+ cells
No adverse effects. 2 subjects’ cells detected
containing both the RRE and LN vectors on the day
after cell infusion. All subsequent samples negative for
the L-RRE-neo vector. Cells containing the control LN
vector detected up to 330 days.
Rev/tat ribozyme [34]
Tat and tat/rev ribozyme in autologous CD34+ cells
and empty vector backbone in two patient groups
with and without ablation
Trial 1: 3/5 patients showed low-frequency marking of
PBMC with ribozyme and vector backbone. Trial 2:
gene marked cells detected after infusion and to 1 year
and RNA expression detected.
Tat/vpr ribozyme [4]
Phase I study: Moloney murine leukemia retroviral
vector encoding a ribozyme versus control LNL6
vector in CD34+ HPSC
De novo production of myeloid and lymphoid cells.
Degree of persistence of gene-containing cells
dependent on transduced cell dose.
Tat/vpr ribozyme [32]
Phase II study: Moloney murine leukemia
virus-based, replication-incompetent gamma
retroviral vector with gene encoding a ribozyme vs
placebo in CD34+ cells
No significant difference mean plasma viral load at
primary endpoint but lower TWAUC and other
indicators of biologic effect. No safety concerns.
Tat/rev, CCR5, TAR
decoy [35]
Tat/rev short hairpin RNA, TAR decoy, and CCR5
ribozyme expressed from a self-inactivating lentiviral
vector transduced in CD34+ cells, along with standard
unmanipulated HPCs in 4 patients with HIV and
non-Hodgkin’s lymphoma
Engraftment by 11 days. Low levels of gene marking
observed up to 24 months.
monitored in the subjects, and it was estimated that 0.001–
0.01% gene-containing progeny cells were present in the
subjects’ peripheral blood. Transgene expression was shown
in peripheral blood mononuclear cells and T-cell subsets
including naive (CD45RA+CD62L+) T lymphocytes. In the
phase II trial [32], OZ1 gene marking (DNA) and expression
(RNA)were also assessed, with the degree of gene marking in
peripheral blood mononuclear cells higher than in the phase
I trial at 0.01–0.38%.
7. Efficacy in Phase II Trial [32]
Statistical evidence of antiretroviral efficacy found in the
phase II trial was as follows (OZ1 versus control):
(1) Plasma viral load;
(a) greater number of subjects with a plasma viral
load of less than 4 log10 copies/mL at weeks
47/48 (15/32 versus 5/33) (P = .009);
(b) longer median time (36 versus 24 days) to reach
4 log10 copies/mL viral load during the analytic
treatment interruption.
(2) The time-weighted area under the log viral load
curve (TWAUC) was statistically lower in the OZ1
group (weeks 40–48; median difference −0.34 log10
copies/ml/day, P = .024 and weeks 40–100; median
difference −0.37 log10 copies/ml/day, P = .034).
(3) The number of participants with a TWAUC in the
lowest quartile during weeks 40–100 was statistically
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Figure 2: The figure shows the prototypic phase I trial design
in which CD34+ HSC were obtained from post G-CSF apheresis
product that is CD34+ selected. The CD34+ cells were then
transduced with either control or OZ1-containing vector and both
transduced populations (control and OZ1) mixed and infused into
the individual. (1) Subjects are injected with a course of G-CSF
to mobilize CD34+ HSC from the bone marrow to the peripheral
blood. (2) Apheresis product is obtained. (3) The mononuclear cell
fraction is applied to a CD34+ isolation system. (4) CD34+ cells
are obtained. (5) These are transduced with either control or OZ1-
containing vector (50% of each) to obtain (6) A mixed population
of control and OZ1 transduced cells. (7) This mixed population is
infused back into the individual.
greater in the OZ1 group (OZ1 n = 12; 37.5%,
Control n = 5; 15.2%, P = .04).
(4) Median plasma viral load in the OZ1 participants
who continued to display OZ1 expression in PBMC
at any time point beyond week 48 (3.81 log10 95%
CI; median 3.18–4.23; n = 15) was significantly
lower than that in the control participants (4.58
log10 95% CI; median 4.31–4.83; n = 33) (P =
.003). The median TWAUC from weeks 40–48 in
these OZ1 participants (3.44 log10 copies/ml/day, n =
15) was significantly lower than that in the control
participants (3.93 log10 copies/ml/day, n = 33) (P =
.03) as was the median TWAUC from weeks 40–100
(3.97 log10 copies/ml/day, n = 15) in comparison to
the control group (4.53 log10 copies/ml/day, n = 33)
(P = .005).
Other trends were as follows.
(1) Mean plasma viral load was lower in the OZ1 group
at 47/48 week (primary endpoint).
(2) During the analytic treatment interruption, 17 (45%)
participants in the OZ1 group reinitiated HAART
compared to 22 (61%) control participants.
(3) Median time to reinitiate antiretroviral therapy dur-
ing analytic treatment interruption was 29.4 weeks in
the control group (n = 22, 61%) and for the OZ1
group was greater than 60 weeks.
(4) CD4+ T lymphocyte numbers and % CD4 were
higher, and CD8+ T lymphocyte numbers lower, in
the OZ1 group.
8. Safety Evaluations in Prototypic
Trials in addition to SAEs
In both prototypic phase I and II clinical trials no replication-
competent retrovirus was detected at any time point. In both
trials no clonal expansion of hematopoietic cells or other
event suggestive of insertional mutagenesis was observed;
predominant integration site analysis was only required in
the phase II trial. The OZ1 target sequence in the HIV-
1 plasma RNA was assessed over time, and there was no
modification at the ribozyme recognition site to prevent
cleavage, or to drive the evolution of resistant virus.
9. Summary of Other Stem Cell
Trials for HIV/AIDS
Other trials that have been conducted in stem cells for the
indication of HIV/AIDS are summarized in Table 1.
10. Discussion
Gene therapy for HIV-positive individuals has the potential
to provide a once-only treatment that reduces viral load,
preserves the immune system, and avoids cumulative toxi-
cities associated with HAART. The two prototypic clinical
trials (phase I and phase II) described used tat/vpr-specific
anti-HIV ribozyme (OZ1) gene-modified autologous HSC.
In these two trials, 10 subjects [4] and 74 subjects [32] were
treated, respectively.
These and trials from other investigators have shown the
safety of the procedure and the anti-HIV agents themselves
as well as the feasibility of the approach in which autologous
CD34+ HSC are taken from the subject, genetically manipu-
lated and given back to the subject. In addition, the phase II
trial demonstrated a significant biologic effect.
The rationale for the prototypic trials was to demonstrate
a “HAART-sparing” function of the therapy, that is, the
ability to decrease, partially or totally, the need for HAART.
While an antiretroviral effect was seen in the phase II study,
it was relatively modest.
Taken together with the other stem cell trials sum-
marised, areas for focus appear to be (i) maximizing the
number of gene-containing HSC transduced and infused
and/or (ii) maximizing the engraftment, proliferation, and
differentiation of these gene-modified cells, possibly by
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Figure 3: (a) The figure shows the prototypic phase II trial design in which CD34+ HSC are obtained from apheresis product that is
CD34+ selected. The cells were then transduced with either sham (medium only) or OZ1-containing vector and that population (control or
OZ1) infused into the individual. (1) Subjects are injected with a course of G-CSF to mobilize CD34+ HSC from the bone marrow to the
peripheral blood. (2) Apheresis product is obtained. (3) The mononuclear cell fraction is applied to a CD34+ isolation system. (4) CD34+
cells are obtained. (5) These are sham transduced (medium alone) or transduced with OZ1 to obtain (6) a control population or OZ1
tranduced cells. (7) This population is infused back into the individual. (b) The figure shows the schedule for the phase II clinical trial. ART,
antiretroviral therapy; ATI: analytic treatment interruption. The primary endpoint was viral load at weeks 47/48. Other end-points were
area under the viral load curve weeks 40–48 and 40–100.
incorporating partial myeloablation; (iii) potentially increas-
ing the effectiveness of the anti-HIV gene(s) used and (iv)
automation of the cell processing procedure. Each of these
points are discussed here.
10.1. Number of Gene-Containing HSC and Subsequent
Engraftment. In both prototypic clinical trials, a dose of 10
× 106 CD34+ HSC/kg could be achieved. Improvements
in mobilisation, CD34+ cell collection, and transduction
compared to the phase I study [4] resulted in a mean
transduced CD34+ cell dose of 5 × 106 cells/kg and an
increase (approximate 2 log10) in the frequency of OZ1-
containing cells in the peripheral blood. In both trials
(reflected in results from other investigator trials), the
frequency of gene-containing cells in the peripheral blood
decreased over time indicating a need to potentially take
care of one or several of the following in relation to the
HSC: (i) maximizing the number of gene-modified cells, (ii)
maximizing the degree of engraftment, (iii) increasing the
degree of proliferation and differentiation, (iv) infusing on
more than one occasion.
It is relevant that, in each trial, transduced HSC infusion
resulted in gene marking in peripheral blood of only a
maximum of 0.01% (phase I trial) [4] and 0.38% (phase
II trial) [32]. It is significant that mathematical modeling
undertaken prior to the phase II trial [42] predicted that,
during the analytic treatment interruption, OZ1 recipients
would experience an initial increase in HIV-1 viral load
followed by the establishment of a lower set point. This is
indeed the result that was seen in the phase II trial itself
[32]. The model predicted that the establishment of OZ1
CD34+ cells in the bone marrow at approximately 5–10%
of total CD34+ cell population could reduce viral load by
0.5 log10 in one year. In this phase II study, bone marrow
aspiration was not performed, and hence the percentage
engraftment is not known. Based on the frequency of cells
containing OZ1 in the Phase II trial (0.01% to 0.38%) in
the peripheral blood, it can be inferred that engraftment
was substantially lower than 5–10%. Previous studies have
also shown that, in the absence of strong selective pressure,
peripheral blood reconstitution with gene-containing cells is
limited [43–46]. Given the engraftment and gene expression
results in the phase II study [32], the antiretroviral effect
of OZ1 was greater than predicted by the modelling.
Candidate mechanisms for this additional effect include an
impact of OZ1 on cell-to-cell transmission in the lymphatic
system, compartmentalisation such that the number of OZ1-
containing cells in the peripheral blood is not representative
of the survival of OZ1-containing cells in sequestered foci
(e.g., the bone marrow and various lymphatic tissues,
such as the GI lymphoid pool), and perhaps protection of
particular cell subpopulations such as antigen-presenting
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cells (including dendritic cells and macrophages) or HIV-
specific CD4+ T lymphocytes. A recent report [47] suggests
that early hematopoietic progenitor cells in the bone marrow
might be infected with HIV. It is possible that OZ1 in
our phase II study targeted this reservoir, and this could
allow for a larger biologic effect than that predicted by the
mathematical model.
It is also of high interest to explore ways to expand and
ensure efficient engraftment in vivo by use of factors such as
SDF-1 and growth factors/cytokines/differentiation factors.
Therefore, by increasing the transduction efficiency, facilitat-
ing engraftment of these reinfused cells, and potentially using
multiple infusions of transduced cells over time, it may be
possible to increase the number of these gene-protected cells
to see an even greater antiretroviral effect in the future.
10.2. Increased Efficacy of the Anti-HIV Agent and Potential
Use in Different Patient Populations. In both clinical trials,
the gene transfer agent was a retroviral vector delivering
a tat/vpr-specific anti-HIV ribozyme. While effective at
inhibiting HIV in tissue culture systems, it may be that this
agent will need to be used in combination with other anti-
HIV genes or other agents to produce a greater therapeutic
effect and to overcome potential resistance. The use of
multiple agents targeting several sites in the viral replication
cycle is now a well-established concept in anti-HIV therapy.
In the phase I and phase II trials described here, individ-
uals were recruited who were on a relatively (phase I) or fully
(phase II) effective HAART regimen. Future evaluation may
include individuals prior to HAART initiation in whom viral
load (and hence selective pressure for gene-containing cells)
will be higher without the need for treatment interruptions.
Other potential patient groups consist of individuals who are
multidrug resistant or have AIDS and have no other options
for therapy. It should be possible to trial this therapy on these
varying patient populations and eventually there may be an
indication that includes all HIV positive individuals.
10.3. Automation of Cell Processing. The cell processing
procedures used in the phase I and II trials were multi-
step, requiring skilled operators and a variety of equip-
ment/devices. Automation of this process, using a completely
closed system, would be highly desirable to (i) reduce
operator time and effort and the potential for errors, (ii)
potentially increase reproducibility and reliability of the
approach, and (iii) avoid the risk of contamination. Such an
automated and closed system would be highly desirable for
high patient access and reduced cost of cell processing.
10.4. Areas for Maximizing Effect. These can be summarized
as
(i) number of gene-containing cells in the peripheral
blood and lymphatic tissue;
(ii) apparent efficacy of anti-HIV agent;
(iii) improve relatively laborious cell processing.
10.5. Positive Outcomes. Notwithstanding the areas for max-
imizing effect, the prototypic studies indicate that OZ1 cell-
delivered gene therapy is safe and has antiretroviral activity,
albeit modest. Our phase II trial also showed that a large
number of subjects (74) can be treated similarly at several
(3) distinct clinical sites, indicating that this type of approach
can be scaledup to treat substantial numbers of patients,
if personnel at the clinical site are properly trained in cell
processing and delivery. These trials show the potential of
the gene therapy approach for the treatment of HIV-1 and
represent a major advance in the field.
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